Dossier assessment
Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FMS-like tyrosine kinase 3 mutation-positive
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.
Project details
- Project no.
- A23-110
- Commission
- Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A23-110_en
Connected Projects
-
Dossier assessment
Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110
Status: Commission completed